N2OFF (NITO) announced the closing of the merger with MitoCareX Bio, a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the mitochondrial SLC25 protein family.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NITO:
- N2OFF Regains Nasdaq Compliance with Bid Price
- N2OFF regains compliance with Nasdaq min bid price requirement
- N2OFF shareholders approve acquisition of SciSparc subsidary
- N2OFF Stockholders Approve Acquisition of MitoCareX
- Upcoming Stock Splits This Week (September 22 to September 26) – Stay Invested